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In recent years, anticonvulsant activity of many
2-azaspiro[4.4]nonane- and [4.5]decane-1,3-diones
(spirosuccinimides) with different substituents at the
imide nitrogen atom have been described (1-4).
These molecules were found to be active in the max-
imal electroshock (MES) and/or pentylenetetrazole
(scPTZ) seizure tests, the most widely used seizure
models for early identification of new anticonvul-
sants. The structure activity relationship studies con-
ducted with these groups of compounds revealed
that their efficacy depended highly on the size of the
cycloalkyl system attached to the C3 spiro carbon
atom and the kind of aromatic substituent at the
nitrogen atom of pyrrolidine-2,5-dione ring.
Moreover it was proven that the introduction of the
methylene or imine linker between the endocyclic
nitrogen atom and aromatic moiety increased anti-
convulsant activity (5-10). Among these derivatives
the most active were compounds I-III presented in
Figure 1.
Based on these facts, in the present studies we
have designed and synthesized a series of 2-aza-
spiro[4.5]decane-1,3-diones, 7-methyl-, and 8-
methyl-2-azaspiro[4.5]decane-1,3-diones with dif-
ferently substituted aromatic rings connected to the
imide nitrogen atom directly or by methine, methyl-
ene or imine spacers.
The starting 1-carboxy-1-cyclohexane-, 1-car-
boxy-1-(3-methylcyclohexane)-, and 1-carboxy-1-
(4-methylcyclohexane)- acetic acids were prepared
as reported previously (11). The final compounds
[IV-XIX] were obtained in a one-pot cyclization
reaction of the prepared dicarboxylic acids and
appropriately substituted phenylamine, 1-
phenylethylamine, diphenylmethylamine, phenylhy-
drazine, benzylamine or aminopyridine, by heating
them at ca. 190-200OC for 1.5 h. The synthetic pro-
cedures are shown in Scheme 1.
The 1H NMR spectra of the compounds syn-
thesized were studied and revealed characteristic
chemical shifts. The protons of cyclohexane rings
were observed as multiplets within a range of δ
1.27-1.98 ppm [IV-XIII] and δ 1.22-2.10 ppm for
compounds XIV-XIX. The imide protons were
observed as quartets at δ 2.72 ppm [V, VII], as sin-
glets ranging from δ 2.52 ppm to δ 3.15 ppm [IV,
VI, VIII-XVII] or as doublets at δ 2.63 ppm [XIX]
and δ 2.66 [XVIII]. For all the compounds with the
-NH- linker [X, XI, XV-XIX], the amine protons
were observed as broad singlets ranging from δ 6.08
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Figure 1. Structures of anticonvulsant active compounds I-III.
Scheme 1. Synthesis of compounds IV ñ XIX
Compound R X R1 Y R2
IV H - - CH 2-NH2  
V H - - CH 2-OCH3
VI H - - CH 3-OCH3  
VII H - - CH 2,5-OCH3  
VIII H CH CH3 CH H  
IX H CH C6H5 CH H  
X H NH - CH 3-Cl  
XI H NH - CH 4-Cl  
XII H - - N 6-NH2  
XIII H - - N 5-CH3  
XIV 3-CH3 CH2 - CH 2-CF3  
XV 3-CH3 NH - CH H  
XVI 3-CH3 NH - CH 2-CH3  
XVII 3-CH3 NH - CH 4-CH3  
XVIII 4-CH3 NH - CH H  
XIX 4-CH3 NH - CH 4-CH3  
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ppm to δ 6.45 ppm. The proton of methine spacer
[VIII, IX] was observed as a quartet at δ 5.42 ppm
[VIII] or as singlet at δ 6.52 ppm [IX]. The reso-
nance signals of aromatic protons were well separat-
ed and were observed within a range of δ 6.52-7.47
ppm. For the details see Tables 2 and 3.
EXPERIMENTAL
Chemistry
All the chemicals and solvents were purchased
from Merck (Darmstadt, Germany) and were used
without further purification. Melting points (m.p.)
were determined in open capillaries on a B¸chi 353
melting point apparatus (B¸chi Labortechnik,
Flawil, Switzerland) and are uncorrected. The puri-
ty of the compounds was confirmed by thin-layer
chromatography (TLC) on silica gel 60 F254 alu-
minium sheets (Merck; Darmstadt, Germany), using
the developing systems: chloroform : acetone (9 : 1,
v/v). Spots were detected by their absorption under
UV light (λ = 254 nm) and by visualization with
0.05 mol I2 in 10% HCl. The chemical structures
were confirmed by elemental and spectral analyses
(1H NMR). 1H NMR spectra were obtained on a
Varian Mercury 300 MHz spectrometer (Varian
Inc., Palo Alto, CA, USA), in CDCl3, with TMS as
an internal standard. Chemical shifts are reported in
Table 1. Physicochemical data for compounds IV-XIX.
Molecular Yield % Analysis (calculated/found)Compd. 
Formula/Weight M.p.
Rf
[OC]     %C %H %N   
IV
C15H18N2O2 62 69.83 7.03 10.89 0.68258.32 193-195 69.77 6.88 10.69   
V
C16H19NO3 68 70.40 7.02 5.13 0.83273.33 139-141 70.71 6.90 5.31   
VI
C16H19NO3 65 70.40 7.02 5.13 0.86273.33 106-108 70.63 6.99 5.11   
VII
C17H21NO4 67 67.39 6.55 4.62 0.88303.36 105-107 67.60 6.80 4.91   
VIII
C17H21NO2 70 74.79 7.75 5.13 0.92273.38 63-65 70.49 7.32 5.18  
IX
C22H23NO2 70 79.35 6.96 4.21 0.90333.43 133-135 79.55 7.08 4.19   
X
C15H17N2O2Cl1 68 61.70 5.85 9.56 0.70292.76 174-176 61.42 6.00 9.78   
XI
C15H17N2O2Cl1 58 61.70 5.85 9.56 0.72292.76 178-180 61.94 5.60 9.28   
XII
C14H17N3O2 61 64.93 6.62 16.22 0.20259.31 218-220 70.16 6.32 16.48   
XIII
C15H18N2O2 63 69.83 7.03 10.86 0.72258.32 155-157 70.10 7.09 10.58   
XIV
C18H20NO2F3 66 63.78 5.95 4.13 0.92339.35 103-105 63.68 6.11 4.28   
XV
C16H20N2O2 58 70.65 7.41 10.30 0.57272.35 148-150 70.32 7.69 10.00   
XVI
C17H22N2O2 56 71.35 7.75 9.79 0.84286.38 151-153 71.49 7.61 9.49   
XVII
C17H22N2O2 64 71.35 7.75 9.79 0.75286.38 184-186 71.18 7.88 9.90   
XVIII
C16H20N2O2 62 70.65 7.41 10.30 0.60272.35 165-167 70.79 7.23 10.12   
XIX
C17H22N2O2 59 71.35 7.75 9.79 0.80286.38 163-165 71.53 7.91 9.58
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Table 2. 1H NMR data of compounds IV-XIII.
Compd. 1H NMR δ (ppm)/ CDCl3 
IV 1.38-1.98 (10H, m, cyclohexane), 3.15 (2H, s, -CH2-, imide), 4.20 (2H, brs., NH2), 7.31-7.41 (2H, 
m, Harom.), 7.70-7.73 (1H, m, Harom.), 7.91-7.94 (1H, m, Harom.)  
V 1.33-1.97 (10H, m, cyclohexane), 2.72 (2H, q, -CH2-, imide, J = 18.20 Hz), 3.74 (3H, s, OCH3), 
6.98-7.05 (2H, m, Harom.), 7.16 (1H, dd, Harom., J = 7.69 Hz.), 7.36-7.42 (1H, m, Harom.)  
VI 1.32-1.96 (10H, m, cyclohexane), 2.72 (2H, s, -CH2-, imide), 3.81 (3H, s, OCH3) 6.80-6.95 (3H, m, 
Harom.), 7.36 (1H, t, Harom., J = 8.20 Hz)  
VII 1.32-1.94 (10H, m, cyclohexane), 2.72 (2H, q, -CH2-, imide, J = 17.95 Hz), 3.73 (3H, s, OCH3), 3.76 
(3H, s, OCH3), 6.68 (1H, t, Harom., J = 1.54 Hz), 6.93 (2H, d, Harom., J = 1.80 Hz)  
VIII 1.27-1.81 (10H, m, cyclohexane), 1.84 (3H, s, -CH3), 2.52 (2H, s, -CH2-, imide), 5.42 (1H, dd, -CH-, 
J = 7.43 Hz), 7.28-7.37 (3H, m, Harom.), 7.41-7.45 (2H, m, Harom.)
IX 1.27-1.85 (10H, m, cyclohexane), 2.58 (2H, s, -CH2-, imide), 2.67 (2H, s, imide), 6.04 (1H, brs, 
-NH-), 6.52-6.57 (2H, m, Harom.), 6.77-6.80 (1H, m, Harom.), 7.11 (1H, t, Harom., J = 7.82 Hz)  
X 1.36-1.96 (10H, m, cyclohexane), 2.69 (2H, s, -CH2-, imide), 6.13 (1H, brs, -NH-), 6.62-6.68 (1H, 
m, Harom.), 6.70 (1H, t, Harom., J = 2.05 Hz), 6.94-6.98 (1H, m, Harom.), 7.16 (1H, t, Harom., J = 8.08 Hz)  
XI 1.36-1.95 (10H, m, cyclohexane), 2.67 (2H, s, -CH2-, imide), 6.08 (1H, brs, -NH-), 6.68-6.72 (2H, 
m, Harom.), 7.17-7.21 (2H, m, Harom.)  
XII 1.30-1.94 (10H, m, cyclohexane), 2.72 (2H, s, -CH2-, imide), 4.75 (2H, brs, -NH2), 6.52-6.59 (2H, 
m, Hpyridine), 7.54-7.60 (1H, m, Hpyridine)  
XIII 1.32-1.97 (10H, m, cyclohexane), 2.34 (3H, s, -CH3), 2.77 (2H, s, -CH2- imide), 7.19 (1H, d, Hpyridine, 
J = 8,20 Hz), 7.34-7.67 (1H, m, Hpyridine), 8.47 (1H, dd, Hpyridine J = 1.54 Hz)  
Table 3. 1H NMR data of compounds XIV-XIX.
Compd. 1H NMR δ (ppm)/ CDCl3 
XIV
1.06 (3H, d, -CH3, J = 5.85 Hz), 1.48-1.87 (9H, m, cyclohexane), 2.78 (2H, s, -CH2-, imide), 4.74 
(2H, s, -CH2-), 7.06-7.09 (2H, m, Harom.), 7.28-7.38 (2H, m, Harom.)  
XV
1.00 (3H, d, -CH3, J = 6.05 Hz), 1.56-1.90 (9H, m, cyclohexane), 2.71 (2H, s, -CH2-, imide), 6.14, 
(1H, brs, -NH-), 6.78-6.80 (2H, m, Harom.), 7.01 (1H, t, Harom., J = 6.33 Hz), 7.28-7.31 (2H, m, Harom.)  
XVI 
0.96 (3H, d, -CH3, J = 5.90 Hz), 1.22-1.87 (9H, m, cyclohexane), 2.35 (3H, s, -CH3), 2.69 (2H, s, 
-CH2-, imide), 6.45 (1H, brs, -NH-), 6.89 (1H, t, Harom., J = 5.13 Hz), 6.92-7.12 (3H, m, Harom.)  
XVII 
0.95 (3H, d, -CH3, J = 5.90 Hz), 1.22-1.86 (9H, m, cyclohexane), 2.26 (3H, s, -CH3), 2.65 (2H, s, 
-CH2-, imide), 6.43 (1H, brs, -NH-), 6.68, (2H, t, Harom J = 6.67 Hz), 7.03-7.06 (2H, m, Harom.)  
XVIII
1.04 (3H, d, -CH3, J = 6.05 Hz), 1.51-2.10 (9H, m, cyclohexane), 2.66 (2H, d, -CH2-, imide, J = 11.28 
Hz), 6.11 (1H, brs, -NH-), 6.78-6.81, (2H, m, Harom.), 6.99-7.04 (1H, m, Harom.), 7.28-7.31 (2H, m, Harom.)
0.94 (3H, d, -CH3, J = 6.67 Hz), 1.43-2.04 (9H, m, cyclohexane), 2.26 (3H, s, -CH3), 2.63 (2H, d, 
XIX -CH2-, imide, J = 11.28 Hz), 6.40 (1H, brs, -NH-), 6.68, (2H, d, Harom., J = 8.20 Hz), 7.03 (2H, d, 
Harom., J = 8.46 Hz)  
δ values (ppm) and J values in Hertz (Hz). Signal
multiplicities are represented by the following
abbreviations: s (singlet), brs (broad singlet), d (dou-
blet), dd (doublet of doublets), t (triplet), q (quartet),
m (multiplet). Elemental analyses C, H, N were car-
ried out with an Elementar Vario EL III (Hanau,
Germany) and were within ± 0.4% of the theoretical
values. The physicochemical data, yields, elemental
analyses and Rf values for compounds IV-XIX are
presented in Table 1. The 1H NMR data are shown
in Tables 2 and 3.
General procedure for the preparation of compounds
IV-XIX
To a suspension of 1-carboxy-1-cyclohexane-,
1-carboxy-1-(3-methylcyclohexane)- or 1-carboxy-
1-(4-methylcyclohexane)-acetic acids (0.01 mol) in
10 mL of water, the appropriately substituted phenyl-
amine, 1-phenylethylamine, diphenylmethylamine,
benzylamine, phenylhydrazines or 2-aminopyridine
(0.01 mol) was gradually added. The mixture was
heated in an oil bath with simultaneous distillation
of water. The cyclization reaction was continued in
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190-200OC for 1.5 h. The crude products were crys-
tallized from isopropanol to afford the desired com-
pounds. 
PHARMACOLOGY
Compounds IV-XIX were pharmacologically
pre-evaluated within the Antiepileptic Drug
Development (ADD) program (Epilepsy Branch,
Neurological Disorders Program, National Institute
of the Neurological and Communicative Disorders
and Stroke (NINCDS), Rockville), by use of testing
procedures which have been described elsewhere
(12, 13).
Phase I studies involved three tests: maximal
electroshock (MES), subcutaneous pentylenetetra-
zole (scPTZ) and rotorod test for neurological toxi-
city (NT). Male albino mice (CF-1 strain) and male
albino rats (SpragueñDawley) were used as experi-
mental animals. The animals were housed in meta-
bolic cages and allowed free access to food and
water. The compounds were suspended in 0.5%
methylcellulose/water mixture.
The maximal electroshock test (MES)
In the MES screen, an electrical stimulus of 0.2
s in duration (50 mA in mice and 150 mA in rat at
60 Hz) is delivered via corneal electrodes primed
with an electrolyte solution containing an anesthetic
agent.
The subcutaneous pentylenetetrazole seizure test
(scPTZ)
This screen utilizes a dose of pentylenetetra-
zole (85 mg/kg in mice and 70 mg/kg in rats) that
produces clonic seizures lasting for a period of at
least five seconds in 97% (CD97) of animals tested.
At the anticipated time of testing the convulsant was
administered subcutaneously.
All the compounds were injected intraperi-
toneally into mice at the dose levels of 30, 100, and
300 mg/kg with anticonvulsant activity and neurotoxi-
city assessment at 0.5 and 4 h after administration.
The neurological toxicity (NT)
This was induced by compound and was
detected in mice or rats using standardized rotorod
Table 4. Anticonvulsant screening project (ASP), results in mice for compounds IV-XIX.
Intraperitoneal injection in micea
Compd. MESb scPTZc NTd
0.5 h 4 h 0.5 h 4 h 0.5 h 4 h  
IV - - - - - -  
V - - - 100h 300 -  
VIe 300 - 300 - 300g -  
VII - - - - 300 -  
VIIIf 300 300 - - 100 300  
IX - - - 300 - -  
X - - - - - -  
XI - 100 - - 100 -  
XII 300 - - - 300g -  
XIII - - - - 300 -
XIV - 300 - - - -  
XV - - - - - -  
XVI - - - - 300 -  
XVII - - 300 - - -  
XVIII 300 - - - - -  
XIX - - - - - -  
a) Doses of 30, 100 and 300 mg/kg were administrated. The values in the table indicate the minimum dose (mg/kg), where-
by bioactivity was demonstrated. The dash (-) indicates an absence of activity at maximum dose administrated. b) Maximal
electroshock test. c) Subcutaneous pentylenetetrazole test. d) Rotorod neurotoxicity screen. e) Compound VI was active at a
dose of 100 mg/kg in MES and scPTZ tests at 0.5 h. f) Compound VIII showed anti-MES protection at a dose of 100 mg/kg
at 0.25 h and 1 h.
Response comments: g unable to grasp rotorod, h myoclonic jerks
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test. Untreated control mice or rats, when placed on
the rod, can maintain their equilibrium for a pro-
longed time period. The acute motor impairment can
be demonstrated by the inability of animal to main-
tain equilibrium for a given time.
The results of preliminary screening for com-
pounds IV-XIX are presented in Table 4.
RESULTS
Compounds IV-XIX revealed diversified anti-
convulsant properties. Except VI, which was active
both in MES and scPTZ tests, the other active deriv-
atives were effective only in the MES [VIII, XI, XII,
XIV and XVIII] or scPTZ [V, IX, XVII] test. The
most active N-(2-methoxyphenyl)-2-azaspiro[4.5]
decane-1,3-dione [V] inhibited pentylenetetrazole
induced seizures at a dose of 100 mg/kg and 300
mg/kg (not indicated in Table 4) at 4 h, whereas its
3-methoxy analogue [VI] was effective in the MES
and scPTZ tests at a dose of 300 mg/kg at 0.5 h. The
presence of the second methoxy group at position-5
of the aromatic ring yielded inactive compound VII.
Furthermore, introduction of the -CH- linker
between imide nitrogen atom and phenyl ring [VIII,
IX] increased activity. The anticonvulsant efficacy
of compounds mentioned above depended on the
kind of second substituent at the -CH- group. In case
of methyl phenyl substituents [VIII], anti-MES
activity was observed at a dose of 300 mg/kg at 0.5 h
and 4 h. Additionally, VIII showed protection at a
dose of 100 mg/kg at 0.25 h and 1 h in the MES test.
The replacement of the methyl group into second
phenyl substituent [IX] made the compound active in
the scPTZ screen at a dose of 300 mg/kg at 4 h. The
change of the -CH- spacer to -NH- bridge and the
introduction of chloro atom to aromatic ring at posi-
tion-4 in compound XI, resulted in the activity in the
MES test at a dose of 100 mg/kg at 4 h. Surprisingly,
the 3-Cl analogue [X] was found inactive. Among
the N-pyridin-2-yl derivatives [XII, XIII], only N-
(6-aminopyridyn-2-yl)-2-azaspiro[4.5]decane-1,3-
dione [XII] protected animals in the MES test at a
dose of 300 mg/kg at 0.5 h. Introduction of the
methyl group into the cyclohexane ring at position-3
[XIV-XVII] or at position-4 [XVIII-XIX] made the
compounds less active. In this series, N-(2-trifluo-
romethyl-benzyl)-7-methyl-2-azaspiro[4.5]decane-
1,3-dione [XIV] exhibited anti-MES activity at a
dose of 300 mg/kg at 4 h, whereas N-[(4-
methylphenyl)-amino]-7-methyl-2-azaspiro
[4.5]decane-1,3-dione [XVII] was active in the
scPTZ test at a dose of 300 mg/kg. The ortho-methyl
analogue [XVI] was devoid of activity in both tests
applied. It was in contrast to earlier experiments indi-
cating that the presence of different substituents at
the position-2 of the aryl ring is important for the
anticonvulsant activity (5-7). 
The change of position of methyl group in
spirocyclohexane ring from position-3 to -4, did not
influence the anticonvulsant activity. Among the
para-methyl derivatives only XVIII showed anti-
MES protection at a dose of 300 mg/kg at 0.5 h.
In the neurotoxicity screen, compounds VIII
and XI were toxic at a dose of 100 mg/kg, whereas
the other derivatives V-VII, XII, XIII and XVI
were found to be toxic at a dose of 300 mg/kg.
Compounds IV, IX, X, XIV, XV and XVII-XIX
were devoid of neurotoxicity at the maximum dose
administrated (300 mg/kg). The mice were unable to
grasp rotorod after administration of VI and XII
(300 mg/kg at 0.5 h). Compound V, effective in the
scPTZ test, induced myoclonic jerks at the same
dose in which the anticonvulsant activity was
observed.
In conclusion, the results obtained revealed
that a number of new N-substituted spirosuccin-
imides were moderately effective in the MES or
scPTZ screens, however, none of them was more
potent than the compounds presented in Figure 1
used as the lead structures. There were no clear
structure-activity relationships but it is justified to
claim that all modifications presented in this paper
decreased the anticonvulsant activity in relation to
similar molecules obtained earlier.
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